Pharmaceutical composition containing antibodies directed against the herv-w envelope
AssigneeGeneuro SA
InventorHerve Perron
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition that contains, as an active ingredient, at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the binding site between said env protein and the hASCT1 or hASCT2 receptor.
Claims16
A pharmaceutical composition containing, as an active ingredient, at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the site for binding between said Env protein and the hASCT1 or hASCT2 receptor, and a pharmaceutically acceptable carrier.
A method for treating nervous system pathologies or neuropsychiatric pathologies associated with the interaction of an HERV-W envelope and of an hASCT receptor, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the site for binding between said Env protein and the hASCT1 or hASCT2 receptor.
A method for treating nervous system pathologies or neuropsychiatric pathologies associated with the pro-inflammatory cascade induced by the expression of MSRV/HERV-W, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the site for binding between said Env protein and the hASCT1 or hASCT2 receptor.
An antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the site for binding between said Env protein and the hASCT1 or hASCT2 receptor, said antibody being chosen from the antibodies directed against the glycosylated or nonglycosylated C-terminal end of the SU region of said envelope protein and the antibodies directed against the transmembrane region of said envelope protein.
Dependencies are inferred from the claim text.